News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
238,128 Results
Type
Article (19052)
Company Profile (163)
Press Release (218910)
Multimedia
Podcasts (49)
Webinars (6)
Section
Business (62907)
Career Advice (205)
Deals (9244)
Drug Delivery (64)
Drug Development (34278)
Employer Resources (34)
FDA (6912)
Job Trends (6338)
News (114051)
Policy (11541)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1604)
Academic (1)
Accelerated approval (17)
Adcomms (13)
Allergies (72)
Alliances (18210)
ALS (77)
Alzheimer's disease (741)
Antibody-drug conjugate (ADC) (139)
Approvals (7203)
Artificial intelligence (268)
Autoimmune disease (87)
Automation (19)
Bankruptcy (55)
Best Places to Work (6033)
BIOSECURE Act (7)
Biosimilars (134)
Biotechnology (114)
Bladder cancer (93)
Brain cancer (24)
Breast cancer (323)
Cancer (2452)
Cardiovascular disease (254)
Career advice (191)
Career pathing (7)
CAR-T (154)
CDC (16)
Celiac Disease (1)
Cell therapy (415)
Cervical cancer (13)
Clinical research (30471)
Collaboration (965)
Company closure (1)
Compensation (400)
Complete response letters (19)
COVID-19 (1146)
CRISPR (71)
C-suite (445)
Cystic fibrosis (94)
Data (3617)
Decentralized trials (1)
Denatured (22)
Depression (67)
Diabetes (281)
Diagnostics (2398)
Digital health (22)
Diversity (8)
Diversity, equity & inclusion (13)
Drug discovery (148)
Drug pricing (119)
Drug shortages (19)
Duchenne muscular dystrophy (135)
Earnings (20626)
Editorial (23)
Employer branding (2)
Employer resources (35)
Events (35981)
Executive appointments (488)
FDA (8632)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (7)
Frontotemporal dementia (12)
Funding (660)
Gene editing (142)
Generative AI (29)
Gene therapy (366)
GLP-1 (549)
Government (1720)
Grass and pollen (2)
Guidances (170)
Healthcare (7695)
HIV (40)
Huntington's disease (24)
IgA nephropathy (53)
Immunology and inflammation (99)
Immuno-oncology (31)
Indications (66)
Infectious disease (1274)
Inflammatory bowel disease (124)
Inflation Reduction Act (7)
Influenza (54)
Intellectual property (80)
Interviews (15)
IPO (4427)
IRA (27)
Job creations (741)
Job search strategy (173)
JPM (32)
Kidney cancer (10)
Labor market (18)
Layoffs (145)
Leadership (8)
Legal (1830)
Liver cancer (42)
Longevity (7)
Lung cancer (346)
Lymphoma (240)
Machine learning (21)
Management (11)
Manufacturing (402)
MASH (93)
Medical device (2700)
Medtech (2714)
Mergers & acquisitions (5254)
Metabolic disorders (705)
Multiple sclerosis (79)
NASH (12)
Neurodegenerative disease (148)
Neuropsychiatric disorders (38)
Neuroscience (1358)
NextGen: Class of 2026 (2160)
Non-profit (1718)
Now hiring (15)
Obesity (334)
Opinion (99)
Ovarian cancer (83)
Pain (114)
Pancreatic cancer (93)
Parkinson's disease (132)
Partnered (14)
Patents (155)
Patient recruitment (235)
Peanut (24)
People (23434)
Pharmaceutical (33)
Pharmacy benefit managers (15)
Phase 1 (8502)
Phase 2 (12329)
Phase 3 (11903)
Pipeline (2642)
Policy (150)
Postmarket research (1440)
Preclinical (3374)
Press Release (16)
Prostate cancer (123)
Psychedelics (15)
Radiopharmaceuticals (160)
Rare diseases (506)
Real estate (1630)
Recruiting (12)
Regulatory (10391)
Reports (13)
Research institute (1410)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (11)
RSV (32)
Schizophrenia (78)
Series A (129)
Series B (102)
Sickle cell disease (75)
Special edition (8)
Spinal muscular atrophy (91)
Sponsored (17)
Startups (1391)
Stomach cancer (7)
Supply chain (50)
Tariffs (52)
The Weekly (26)
Vaccines (400)
Venture capital (42)
Weight loss (219)
Women's health (41)
Worklife (1)
Date
Today (49)
Last 7 days (274)
Last 30 days (1022)
Last 365 days (14146)
2026 (1464)
2025 (14238)
2024 (15603)
2023 (16915)
2022 (21183)
2021 (22016)
2020 (20101)
2019 (17329)
2018 (13023)
2017 (12198)
2016 (11388)
2015 (12248)
2014 (8624)
2013 (7126)
2012 (7240)
2011 (7268)
2010 (5910)
Location
Africa (246)
Alabama (30)
Alaska (1)
Arizona (60)
Arkansas (3)
Asia (15939)
Australia (2188)
California (5020)
Canada (1154)
China (583)
Colorado (165)
Connecticut (247)
Delaware (228)
Europe (36062)
Florida (687)
Georgia (134)
Hawaii (1)
Idaho (15)
Illinois (399)
India (37)
Indiana (327)
Iowa (7)
Japan (316)
Kansas (54)
Kentucky (9)
Louisiana (11)
Maine (28)
Maryland (503)
Massachusetts (4177)
Michigan (48)
Minnesota (135)
Mississippi (1)
Missouri (68)
Montana (9)
Nebraska (4)
Nevada (32)
New Hampshire (14)
New Jersey (1731)
New Mexico (11)
New York (1410)
North Carolina (647)
North Dakota (6)
Northern California (2620)
Ohio (124)
Oklahoma (5)
Oregon (23)
Pennsylvania (975)
Puerto Rico (4)
Rhode Island (17)
South America (303)
South Carolina (9)
Southern California (1829)
Tennessee (46)
Texas (602)
United States (18116)
Utah (153)
Vermont (1)
Virginia (131)
Washington D.C. (44)
Washington State (428)
Wisconsin (49)
238,128 Results for "chroma medicine inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Chroma Medicine Announces Exclusive License Agreement with the Whitehead Institute for Novel Epigenetic Editing Technology
Chroma Medicine, Inc. (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced it has entered into an exclusive license agreement with the Whitehead Institute to access intellectual property and technology developed in the lab of Chroma co-founder Jonathan Weissman, Ph.D.
June 27, 2024
·
2 min read
Business
Chroma Medicine Announces Appointment of Jenny Marlowe, Ph.D., as Chief Development Officer
Chroma Medicine, Inc. today announced the appointment of Jenny Marlowe, Ph.D., as the Company’s Chief Development Officer.
May 20, 2024
·
2 min read
Press Releases
Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines
December 11, 2024
·
5 min read
Business
Chroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its Board of Directors
Chroma Medicine, Inc. announced the addition of innovative biotech business leader Michael A. Kelly to its Board of Directors.
September 27, 2023
·
2 min read
Genetown
Chroma Medicine Highlights Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting
Chroma Medicine, Inc. presented data demonstrating the potential of its multiplex epigenetic editing platform to enhance functional allogeneic chimeric antigen receptor T cells at the American Society of Hematology 65th Annual Meeting in San Diego.
December 10, 2023
·
3 min read
Business
Chroma Medicine Demonstrates Robust and Durable HBV Silencing with CRMA-1001 at 2024 International HBV Meeting
September 16, 2024
·
3 min read
Press Releases
Chroma Medicine Appoints Renowned RNA Scientist Melissa Moore to Board of Directors
July 19, 2024
·
2 min read
Press Releases
Sphere Fluidics Launches Cyto-Mine Chroma and Announces Early Access Program
January 27, 2025
·
2 min read
Genetown
Chroma Medicine to Showcase Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting
Chroma Medicine, Inc. announced that it will present a poster demonstrating the potential of its multiplex epigenetic editing platform at the American Society of Hematology 65th Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.
November 2, 2023
·
1 min read
Genetown
Chroma Medicine Presents Data Showing Specific and Durable HBV Silencing with Epigenetic Editors at the HBV International Meeting 2023
Chroma Medicine, Inc., a genomic medicine company pioneering single-dose epigenetic editing therapeutics, presented positive preclinical data demonstrating the potential of its epigenetic editors to produce efficacious, specific, and durable silencing of the hepatitis B virus during the HBV International Meeting 2023, held September 19-23 in Kobe, Japan.
September 20, 2023
·
3 min read
1 of 23,813
Next
